

Contents

Part I Introduction and Background

1	Introduction to Systems Approaches to Cancer	3
	Frederick B. Marcus and Alfredo Cesario	
1.1	Cancer and Systems Approaches	3
1.1.1	Nature and Causes of Cancer	3
1.1.2	The Progression of Cancer	4
1.1.3	Cancer: Clinical Background and Key Challenges	5
1.1.4	Systems Biology Approaches to Cancer	6
1.1.5	Key Books and Reviews of Systems Approaches	7
1.1.6	Importance of Legal and Ethical Considerations	9
1.2	Laboratory, Clinical, Data and Educational Resources	9
1.2.1	Global Molecular and Cellular Measurement Technologies	9
1.2.2	Cell Lines, Tissue Samples, Model Organisms, Biobanks	10
1.2.3	Expression and Genetic Variation Databases for Cancer Research	11
1.2.4	Education and Research Infrastructures	11
1.3	Bioinformatics and Systems Biology Analysis	12
1.3.1	Mathematical Tools in Cancer Signalling	12
1.3.2	Computational Tools	13
1.3.3	The Hallmarks of Cancer Revisited Through Modelling	14
1.3.4	Analysis of Cell Death Pathways in Cancer: The Role of Collaborative and Interdisciplinary Research	14
1.3.5	Approaches to Cancer Progression Outcomes	16
1.3.6	Modelling at the Physiological and Tumour Level	16
1.4	Diagnosis and Treatment Applications	17
1.4.1	Diagnostic and Prognostic Cancer Biomarkers	17
1.4.2	Cancer Drug Development	18
1.4.3	Cancer Chronotherapy	19
1.4.4	Clinical Applications of Systems Biology Approaches	19
1.4.5	Cancer Robustness and Therapy Strategies	20

1.5	Perspectives and Conclusions	21
1.5.1	Perspectives	21
1.5.2	Conclusion	21
	References	22
2	Cancer: Clinical Background and Key Challenges	29
	Antonio Llombart-Bosch, Ulrik Ringborg, Sergio Rutella and Julio E. Celis	
2.1	Introduction	29
2.2	Pathology Integration in Cancer Biology Systems	31
2.2.1	Definition of a Neoplasm	32
2.2.2	Tumour Nomenclature	33
2.2.3	Tumour Grading	35
2.2.4	Growth Rate of a Tumour	38
2.2.5	Dysplasia and Carcinoma in situ	39
2.2.6	Metastasis	41
2.2.7	Tumour Staging	42
2.2.8	Cytology and Diagnosis	45
2.3	Technological Approaches to Morphology and Pathology	46
2.3.1	Hematoxylin-Eosin (H&E) Staining in Histological Diagnosis	46
2.3.2	Immunohistochemistry	46
2.3.3	Electron Microscopy	47
2.3.4	Tissue Microarray (TMA)	48
2.4	Treatments	49
2.4.1	Surgical Treatment	50
2.4.2	Radiation Therapy	50
2.4.3	Systemic Treatment	51
2.4.4	Treatment Strategies	58
2.5	Major Cancers, Diagnosis, Disease-specific Supplementary Classifications, and Treatment Implications	60
2.5.1	Colorectal Cancer	60
2.5.2	Breast Carcinoma	63
2.5.3	Lung Cancer	69
2.5.4	Small Round Cell Tumours (SRCT)	73
2.5.5	Leukaemias and Lymphomas	77
2.6	Systems Biology of Cancer: Key Challenges for the Future	81
	Acknowledgements	84
	References	84
 Part II Laboratory, Clinical, Data and Educational Resources		
3	Global Molecular and Cellular Measurement Technologies	97
	Bodo M. H. Lange, Michal R. Schweiger and Hans Lehrach	
3.1	Introduction—The Need for Systems Biology Predictive Models	99

3.2	Sample Preparation	100
3.3	Analysis of the Genome	102
3.3.1	DNA Microarrays	102
3.3.2	Next Generation Sequencing (NGS)	102
3.4	Proteomics	110
3.4.1	Two-dimensional Gel Electrophoresis	110
3.4.2	Mass Spectrometry	111
3.4.3	Quantitative Protein Arrays	112
3.4.4	Immunohistochemistry	113
3.4.5	Phosphoproteome	114
3.4.6	Metabolome	115
3.5	Functional Studies	115
3.5.1	RNA Interferences (RNAi)	116
3.5.2	Model Organisms	117
3.5.3	Determining Drug and Compound Action	118
3.5.4	Protein-Protein and Protein-DNA Interactions	119
3.6	Overall Determining Factors and Future Outlook	120
	Acknowledgments	121
	References	121
4	Cell Lines, Tissue Samples, Model Organisms, and	
	Biobanks: Infrastructure and Tools for Cancer Systems Biology	127
	Sandra Tomaszek and Dennis A. Wigle	
4.1	Introduction	127
4.2	Human Cell Lines	128
4.2.1	The NCI-60 Human Cancer Cell Line Panel	129
4.3	Model Organisms	131
4.3.1	Transgenic Mouse Models	132
4.3.2	Chemically Induced Models	134
4.3.3	Human Lung Tumour Xenografts	134
4.3.4	Lung Cancer Models in Cancer Drug Development	137
4.3.5	Models for the Study of Lung Cancer Metastasis	138
4.3.6	Model Organisms: New Systems for Modelling Cancer	139
4.3.7	Restrictions on the Use of Animals in Research	141
4.4	Patient Biobanks	141
4.4.1	Paraffin Embedded Tissues	142
4.4.2	Snap-frozen Tissues	142
4.4.3	Linking Molecular and Clinical Measurements	143
4.5	Role of Interactome Maps and Crucial Pathways	144
4.5.1	Links to Specific Types of Cancer	144
4.5.2	Synthetic Lethality as a Network-derived Treatment Success-story	145
4.6	Integration into Systems and Computational Approaches	146
4.7	The Future: Data Integration to Systems-level Experiments	147
	References	147

5	Expression and Genetic Variation Databases for Cancer Research	153
	Johan Rung and Alvis Brazma	
5.1	Introduction	153
5.2	Genetic Variation	154
5.2.1	SNP Databases	155
5.2.2	Databases of Structural Variants	155
5.2.3	Databases for Disease-causing Variants	156
5.2.4	Large-scale Repositories for Experiments	157
5.2.5	Reference Genomes	158
5.3	Gene Expression	159
5.3.1	Archives of Gene Expression Data	159
5.3.2	Added-value Databases	160
5.4	Informatics Coordination by International Consortia	161
	References	163
6	Education and Research Infrastructures	165
	Anna Tramontano and Alfonso Valencia	
6.1	The Challenge	165
6.2	The Actors	167
6.2.1	Molecular and Cell Biologists	167
6.2.2	Chemical Biologists	168
6.2.3	Clinical Oncology Researchers	169
6.2.4	General Public	171
6.3	Training and Education of the Stakeholders	172
6.3.1	The Core Subjects in Modern Scientific Education	172
6.3.2	User Training	174
6.3.3	The General Public	176
6.4	Organization of Cancer Research Centres and their Cross-disciplinary Activities	177
6.5	Conclusions	180
	Acknowledgments	180
	References	180

Part III Bioinformatics and Systems Biology Analysis

7	Mathematical Tools in Cancer Signalling Systems Biology	185
	Julio Vera and Olaf Wolkenhauer	
7.1	Introduction	185
7.2	The Systems Approach	188
7.2.1	When to Employ a Systems Biology Approach	188
7.2.2	Biological Hypothesis and Set-up of the Signalling System	190
7.2.3	Mathematical Modelling	192
7.2.4	Experimental Techniques Used for Producing Quantitative Data	196
7.2.5	Model Calibration: Parameter Estimation and	

Model Refinement	199
7.2.6 Model Analysis	200
7.2.7 Data Visualization	204
7.3 Discussion	206
7.4 Appendix	208
Acknowledgements	208
References	209
8 Computational Tools for Systems Biology	213
Edda Klipp and Falko Krause	
8.1 Introduction	213
8.2 Standards in Systems Biology	216
8.2.1 Standards Support Communication in Biological Research ..	216
8.2.2 Language Formats	217
8.2.3 Ontologies	222
8.3 Web Resources	223
8.3.1 JWS Online and BioModels Database	224
8.3.2 KEGG	225
8.3.3 Reactome	226
8.3.4 BioCyc	226
8.3.5 BRENDA	227
8.3.6 SABIO-RK	227
8.4 Computational Tools	228
8.4.1 Tools for Model Formulation and Simulation	229
8.4.2 Spatial and Temporal Simulation	231
8.4.3 Boolean and Logical Models	231
8.4.4 General Purpose Tools	232
8.5 Visualizing Networks	234
8.6 Workflows	235
8.6.1 Taverna Workbench	237
8.7 Discussion	237
Acknowledgements	238
References	238
9 The Hallmarks of Cancer Revisited Through Systems	
Biology and Network Modelling	245
Charles Auffray, Trey Ideker, David J. Galas and Leroy Hood	
9.1 Introduction	245
9.1.1 Hallmarks of Cancer	245
9.1.2 Network Properties	246
9.1.3 Advances in Hallmark Analysis and Networks	246
9.2 The Potential of Systems Approaches to Disease	247
9.2.1 Principles of Systems Biology	247
9.2.2 Challenges in Modelling Networks in Cancer	248
9.2.3 Network Inference Through Machine Learning	249

9.2.4	An Illustrative Example: Systems Biology of Prion Disease	250
9.3	Transcription and Protein Interaction Networks Revealed by Modular Cancer Biomarkers	251
9.3.1	Networks and Biomarkers	251
9.3.2	Proteomics and Pathways	251
9.4	Growth, Proliferation and Apoptosis Revisited Through Signalling Network Modelling	252
9.4.1	Signalling Pathways	252
9.4.2	Growth Factors and Apoptosis	253
9.5	Sustained Angiogenesis and Metastasis Revisited Through Multiscale Modelling	254
9.5.1	Mathematical Modelling	254
9.5.2	Angiogenesis	254
9.5.3	Metastasis	254
9.6	The Hallmarks of Cancer Extended to the Control of Metabolism and Stress	255
9.6.1	Cancer as a Metabolic Disease	255
9.6.2	Beyond Oncogene Addiction	256
9.7	Conclusions and Perspectives	256
9.7.1	Genome Variation and Instability Revisited Through Genetic and Genomic Networks	256
9.7.2	Novel Avenues for Diagnosis, Therapy and Disease Network Modelling	257
9.7.3	Frontier Challenges: Multiscale Integration and Cross-disciplinarity	258
	Acknowledgements	259
	References	259
10	Systems Biology Analysis of Cell Death Pathways in Cancer:	
	How Collaborative and Interdisciplinary Research Helps	267
	Boris Zhivotovsky and Emmanuel Barillot	
10.1	Introduction	268
10.2	Cell Death Pathways	269
10.2.1	The Death Receptor-mediated Pathway	271
10.2.2	The Mitochondria-mediated Pathway	271
10.2.3	Modulators of Caspase Activity: The IAP Family of Proteins and Their Regulators	272
10.2.4	Cross-talk Between Various Modes of Cell Death	273
10.3	Dysregulation of Cell Death Pathways in Cancer	275
10.3.1	Defects in the Apoptotic Machinery of Tumour Cells	275
10.3.2	Defects in Autophagy-regulated Machinery	279
10.4	Mathematical Modelling of Cell Death Pathways	280
10.4.1	Different Models of Cell Death	280
10.4.2	Modelling Cell-fate Decision Between Survival, Apoptosis and Necrosis	282
10.5	Elements for Interdisciplinary Approaches to Cancer Research	285

10.5.1	Cancers Susceptible to Integrated Systems Approaches ..	285
10.5.2	Laboratory and Clinical Measurements and Resources ...	286
10.6	How to Share Knowledge About Systems Biology Approaches to Cancers (See Also Chap. 6)	288
10.6.1	A Common Language	288
10.6.2	Visualizing Networks as a Stimulus to Reasoning and Exchanges	289
10.6.3	Sharing Network Description and Models	290
10.7	Major Collaborative Efforts	290
10.7.1	Apo-sys: Large Scale Collaborative Research on Apoptosis	290
10.7.2	Cancersys: Medium Scale Collaborative Research on Hepatocellular Carcinoma	291
10.8	Supporting Collaborative Research Projects	291
10.8.1	Enfin: Systems Biology Tool Development and Application to Cancer	291
10.8.2	Gen2phen: Bioinformatics Analysis of Genetic Variation and Application to Colorectal Cancer	292
10.9	Conclusion	292
	Acknowledgements	293
	References	293
11	Systems Biology, Bioinformatics and Medicine Approaches to Cancer Progression Outcomes	297
	Jan G. Hengstler, Mathias Gehrmann, Stefan Höhme, Dirk Drasdo, Joanna D. Stewart and Marcus Schmidt	
11.1	Introduction: The Concept of Pathway Signatures	297
11.2	Identification of Biological Motifs from Gene Array Data	299
11.2.1	Gene Expression Profiling	299
11.2.2	Metagenes for Clusters of Co-regulated Genes	301
11.3	From Biological Motifs to Pathway Activation	303
11.4	How Realistic is Modelling of Carcinogenesis and Tumour Development in Virtual Tissues and Organs?	304
11.4.1	Spatial-temporal Models of Tumours	304
11.4.2	Tumour Modelling Perspectives	305
	References	307
12	System Dynamics at the Physiological and Tumour Level	309
	Robert A. Gatenby	
12.1	Introduction to Mathematical Modelling in Cancer	309
12.1.1	Lessons from History	309
12.1.2	Extension to Bioinformatics and Systems Biology	311
12.2	Mathematical Models in Cancer	311
12.2.1	The Role of Modelling in Cancer Research	311
12.2.2	Aspects of Cancer Modelling	313

12.3	Model Development	314
12.3.1	Historical Perspective—Understanding Tumour as a Complex System	314
12.3.2	Building the Tumour System—Starting with Spheroids ..	314
12.4	Iterative Modelling of Tumour Systems	315
12.5	Experimental Studies of Tumour Invasion	317
12.6	Tumour Modelling Collaborations	318
12.7	Detailed Modelling Example	321
12.7.1	Carcinogenesis Transitions	321
12.7.2	Somatic Evolution	323
12.8	Conclusions	325
	References	325

Part IV Diagnosis, Clinical and Treatment Applications

13	Diagnostic and Prognostic Cancer Biomarkers: From Traditional to Systems Approaches	329
	Francesca M. Buffa and Adrian L. Harris	
13.1	Introduction	329
13.2	Role of Biomarkers	331
13.3	Biomarkers for Prediction of Response to Treatment	331
13.3.1	The ErbB Family of Receptor Tyrosine Kinases: HER2 as a Predictive Marker in Breast Cancer	331
13.3.2	EGFR in Head and Neck, Colorectal and Non- small-cell Lung Cancers	332
13.4	Biomarkers for Prognosis	333
13.4.1	Traditional Clinical Markers—Lymph Node Involvement	333
13.4.2	Histological Grade and Proliferation	333
13.4.3	Gene Expression Grade	334
13.4.4	Proliferation Markers	334
13.4.5	Hypoxia Biomarkers	334
13.4.6	Global and Multi-gene Expression Profiling	335
13.4.7	New Areas for Biomarker Development—microRNA ...	340
13.4.8	Chromosome Aberration	340
13.5	Biomarkers for Monitoring	340
13.5.1	DNA Methylation	341
13.5.2	Mutated Plasma DNA	341
13.6	Measurement and Analysis of Biomarkers	341
13.6.1	Key Measurement Technologies	342
13.6.2	Tissue Arrays	342
13.6.3	Microarrays	343
13.6.4	RNA Analysis	343

13.7	Identification, Standardization and Validation of Effective Biomarkers	344
13.8	Annotated High-quality Clinical Samples	347
13.9	Analyses and Simulations to Predict and Identify Biomarkers	348
13.10	Approaches to Data Analyses in Genomic Studies	348
13.10.1	Class Discovery and Class Prediction	348
13.10.2	Gene and Protein Networks	350
13.10.3	Knowledge-based Class Comparison	351
13.10.4	Knowledge-based Class Prediction and Mining of Genomic Data	351
13.10.5	Literature Data-mining and Data Repositories	352
13.11	Meta-analyses of Biomarker Studies	353
13.12	Quantitative Simulations of Major Pathways Leading to Biomarker Development	353
13.12.1	Simulation of Cancer Pathways: The EGFR Pathway ..	354
13.12.2	Databases and Repositories of Models	355
13.13	Pharmacokinetics and Pharmacodynamics	355
13.14	Integrated Approaches to Biomarker Discovery and Development	356
	References	358
14	Systems Biology Approaches to Cancer Drug Development	367
	Christopher Snell, David Orrell, Eric Fernandez, Christophe Chassagnole and David Fell	
14.1	Introduction	367
14.1.1	The Systems View of Drug Action	367
14.1.2	Introducing Systems Biology into Drug Development ..	370
14.2	Model Building	370
14.2.1	Linking Data to the Models	370
14.3	Case Studies of Modelling Cellular Networks	372
14.3.1	Using Cellular Networks in Drug Development	372
14.3.2	Modelling the Cellular Action of Seliciclib and Other cdk2 Inhibitors	372
14.3.3	Apoptosis and Signal Transduction Pathways	373
14.3.4	Difficulties with Detailed Modelling	374
14.4	Modelling at Cellular Scales	375
14.4.1	'Virtual Tumour' Model as a Simpler Approach	375
14.4.2	Modelling Schedules and Combinations	375
14.4.3	Predicting Schedules in Drug Development	376
14.4.4	Chronotherapy and the TEMPO Project	376
14.5	Technologies Typically Used at a Biotech Company	377
14.5.1	Computing Requirements	377
14.5.2	Model Database and Reports	378
14.5.3	One Operational Example: Delivering the Outputs with ModelPlayer™	378

14.6 Conclusion	378
References	379
15 Circadian Rhythms and Cancer Chronotherapeutics	381
Francis Lévi, Atilla Altinok and Albert Goldbeter	
15.1 Circadian Rhythms in Health and Diseases	381
15.1.1 Biological Evidence	382
15.1.2 Experimentally-based Computational Models	386
15.2 Chronopharmacology, Chronotolerance and Chronoefficacy of Anticancer Drugs	388
15.2.1 Experimental Evidence and Mechanisms	388
15.2.2 Clinical Cancer Chronotherapeutics	391
15.2.3 Probing Circadian Patterns of Anticancer Drug Delivery in silico	394
15.3 From Standard to Personalized Cancer Chronotherapeutics	399
15.3.1 Experimental and Clinical Data	399
15.3.2 Insights from a Modelling Approach	402
15.4 Conclusions and Perspectives	404
Acknowledgments.....	405
References	405
16 Clinical Applications of Systems Biology Approaches	409
Sergio Iadevaia, Adel B. Tabchy, Prahlad T. Ram and Gordon B. Mills	
16.1 Chapter Introduction	409
16.2 Systems Biology Approaches to Identifying Diagnostic, Prognostic, and Therapeutic Biomarkers for Cancer	413
16.2.1 Genomic, Transcriptomic, Proteomic, and Metabolic (Omics) Analysis of Human Tumours	413
16.2.2 Computational Mining of Omics Data	415
16.3 Systems Biology Approaches to the Design of Combinatorial Targeted Therapy for Cancer	417
16.3.1 Animal and Cell Line Models	417
16.3.2 Pharmacodynamic Modelling	419
16.3.3 Pharmacokinetic Modelling	420
16.3.4 Combined Pharmacodynamic-Pharmacokinetic Modelling	420
16.3.5 Combined Therapy Modelling	421
16.3.6 Biopsy and Virtual Biopsy Approaches to Measuring Tumours and Assessing Treatment Activity ...	422
16.4 The Future of Clinical Trials: Applying Systems Approaches to Clinical Trial Design	423
References	424

17 Cancer Robustness and Therapy Strategies	429
Hiroaki Kitano	
17.1 Introduction	429
17.1.1 Cancer as a Robust System	429
17.1.2 What is Robustness?	430
17.1.3 Robustness and Homeostasis	431
17.2 Mechanisms for Robustness	432
17.2.1 System Control	432
17.2.2 Fault-tolerance	432
17.2.3 Modularity	433
17.2.4 Decoupling	433
17.3 Mechanisms for Cancer Robustness	435
17.4 Robustness Trade-offs	436
17.5 Theoretically-motivated Therapeutic Strategies	437
17.6 An Appropriate Index of Treatment Efficacy	441
17.7 Long-tail Drugs	441
17.8 Conclusion	443
Acknowledgements	444
References	444

Part V Perspectives and Conclusions

18 Synthetic Biology and Perspectives	449
Toru Yao and Frederick B. Marcus	
18.1 Introduction	449
18.2 Synthetic Biology for Cancer Research and Applications	450
18.2.1 Introduction to Synthetic Biology	450
18.2.2 Manipulation at the Molecular Level	451
18.2.3 Applications in Cells	452
18.2.4 Synthetic Biology in Japan	453
18.3 Synthetic Biology Applications to Cancer	454
18.3.1 Cancer Biology	454
18.3.2 Diagnostics	455
18.3.3 Drug Development	455
18.3.4 Gene/Protein Therapy	456
18.3.5 Immunotherapy	457
18.4 Review Articles and Workshops—Integrated Perspectives	458
18.4.1 How Systems Biology Can Advance Cancer Research ...	459
18.4.2 Cancer Systems Biology—2nd Workshop	460
18.4.3 Systems Medicine: The Future of Medical Genomics and Healthcare	462
18.5 Resources Needed to Support Systems Approaches to Cancer Research and Diagnosis	463
18.5.1 Infrastructure Requirements for Systems Biology	463
18.5.2 Clinical Resources	464

18.5.3	Data Resources, Analysis and Cancer Modelling Tools ...	464
18.6	Conclusions	465
	References	465
19	Conclusions	471
	Alfredo Cesario and Frederick B. Marcus	
19.1	Key Points	471
19.1.1	Introduction and Background	471
19.1.2	Laboratory, Clinical, Data and Educational Resources for Cancer Research	472
19.1.3	Bioinformatics and Systems Biology Research Results ..	473
19.1.4	Translation to Clinical Applications	475
19.1.5	Perspectives	476
19.2	Overall Conclusions	476
	Index	479

Cancer Systems Biology, Bioinformatics and Medicine
Research and Clinical Applications

Cesario, A.; Marcus, F. (Eds.)

2011, XXVIII, 484 p., Hardcover

ISBN: 978-94-007-1566-0